66410-36-4

Usage

InChI:InChI=1/C9H7ClO6S/c10-17(13,14)5-3-6(9(11)12)8-7(4-5)15-1-2-16-8/h3-4H,1-2H2,(H,11,12)

Upstream product

• 4442-53-9 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid 

Downstream Products

• 66411-38-9 7-cyclohexylsulfamoyl-1,4-benzodioxane-5-carboxylic acid 
• 66410-49-9 7-dimethylsulfamoyl-1,4-benzodioxane-5-carboxylic acid 

Relevant academic research and scientific papers

Sulfanilamide derivative as well as preparation method and application thereof

The invention discloses a sulfanilamide derivative as well as a preparation method and application thereof. The compound has a structure as shown in a formula II. The invention further relates to a preparation method of the compound with the structure shown in the formula II, a pharmaceutical composition and application of the compound in preparation of anti-HBV drugs.

Small Molecule Microarray Based Discovery of PARP14 Inhibitors

Poly(ADP-ribose) polymerases (PARPs) are key enzymes in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, and suffer from poor selectivity. PARP14 has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Herein, we describe a small molecule microarray-based strategy for high-throughput synthesis, screening of >1000 potential bidentate inhibitors of PARPs, and the successful discovery of a potent PARP14 inhibitor H10 with >20-fold selectivity over PARP1. Co-crystallization of the PARP14/H10 complex indicated H10 bound to both the nicotinamide and the adenine subsites. Further structure–activity relationship studies identified important binding elements in the adenine subsite. In tumor cells, H10 was able to chemically knockdown endogenous PARP14 activities.

THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION

Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. The compounds and compositions can be used to modulate an isocitrate dehydrogenase (IDH) mutant (e.g., IDHIm or IDH2m) having alpha hydroxyl neoactivity

Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation

Novel substituted 2,3-alkylene bis (oxy) benzamides and derivatives thereof are disclosed. Also disclosed is a method for producing said compounds. The compounds have anxiolytic, psychostimulant, disinhibiting and thymoanaleptic properties useful therapeutically in the psychofunctional field, particularly in gastro-enterology, cardiology, urology, rheumatology and gynaecology.